Cervical Cancer News and Research

RSS

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

Epitope spreading can get triggered by live, attenuated Listeria vaccine

Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, in collaboration with its scientific founder and Scientific Advisory Board Chair Dr. Yvonne Paterson, have shown that epitope spreading occurs in response to a form of the Company’s proprietary technology that targets tumor blood vessels (anti angiogenic antigen).

8 Oct 2009

Kaiser Permanente launches osteoporosis prevention campaign

Encouraging everyone to “Embrace Your Inner Strength,” Kaiser Permanente has launched a campaign throughout Southern California aimed at getting teenagers, seniors and everyone in between to get serious about building up their skeletons and preventing osteoporosis.

8 Oct 2009

Spectrascience receives Japanese patent for its Optical Biopsy Forceps System and Method of Sampling Tissue

SpectraScience, Inc., a San Diego based medical device company, today announced that it has been awarded Japanese Patent number 4361683 for its Optical Biopsy Forceps System and Method of Sampling Tissue.

8 Oct 2009

NIH grants over $3.8 million to Asuragen

Asuragen, Inc. announced today that it has received over $3.8 million in new grant funding for 2009 from the Small Business Innovative Research (SBIR), Small Business Technology Transfer (STTR), and American Recovery and Reinvestment Act (ARRA) funded initiatives of the National Institutes of Health (NIH) to further its development of molecular diagnostics for oncology and genetic disease.

8 Oct 2009

NCI awards $11.5 million grant to UAB for cervical cancer research

The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center has won an $11.5 million grant from the National Cancer Institute (NCI) to explore groundbreaking cervical cancer research, prevention and treatment.

8 Oct 2009

$16 million federal stimulus funds establish Seattle as national hub for cancer research

Researchers at Fred Hutchinson Cancer Research Center, Group Health Research Institute and the University of Washington schools of Public Health and Pharmacy have been selected to lead four projects backed by approximately $16 million in federal stimulus funding for comparative-effectiveness research in cancer.

7 Oct 2009

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

PDS Biotechnology Corporation today announced that the company has completed GLP toxicology studies of its lead HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the evaluation of toxicity, all demonstrated a very safe profile of the drug and PDS Biotech's platform Versamune((TM)) technology.

6 Oct 2009

mtm laboratories signs additional tranche of Euro 7 million to its Series C funding

mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company’s last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in equity.

6 Oct 2009

Group Health Research Institute to receive federal stimulus funds from ARRA

Group Health Research Institute, formerly Group Health Center for Health Studies, will receive more than $15 million in federal stimulus funding from ARRA, the American Recovery and Reinvestment Act of 2009.

6 Oct 2009

$16 million federal stimulus funds for cancer research projects

6 Oct 2009

Guided Therapeutics awarded $2.5M NCI grant for marketing LightTouch technology

Guided Therapeutics, Inc. today announced that it was awarded a $2.5 million matching grant by the National Cancer Institute (NCI) to bring to market and expand the array features for its LightTouch™ non-invasive cervical cancer detection technology. The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.

6 Oct 2009

Inovio's SynCon H1N1 achieves protective antibody response against pandemic influenza in ferrets

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus (SynConTM) H1N1 influenza vaccine candidates achieved protective antibody responses against the novel pandemic influenza A/H1N1 (2009) in 100% of tested ferrets.

5 Oct 2009

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

5 Oct 2009

Seattle Cancer Care Alliance launches TheDayIFoundOut website for cancer patients

The day a person is diagnosed with cancer is one of the most difficult days of his or her life. While the Internet holds an endless supply of cancer related information, for an overwhelmed and frightened person, genuine emotional support is often hard to find. TheDayIFoundOut(TM) is an online community featuring the faces and voices of cancer survivors offering empathy, insight, advice and resources to help cancer patients take the first crucial steps toward beating their disease.

3 Oct 2009

Study points to subtle differences between boys and girls' attitudes to multiple drugs

New research by Weill Cornell Medical College researchers looks at the specific ways parents and peers influence teenagers to smoke, drink and use marijuana in combination.

3 Oct 2009

Advaxis announces Phase I trial results of its ADXS11-001 therapeutic cancer vaccine

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection.

1 Oct 2009

Screening and diagnostic tests contribute to health care value across spectrum of care

Amidst ongoing debate in Congress over reforming the nation's health care system, a new report from the Lewin Group finds that screening and diagnostic laboratory tests are central to achieving some of the most important goals of health care reform.

1 Oct 2009

Hologic's ThinPrep integrated imager receives CE marking approval

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced it has received CE marking approval for its ThinPrep® integrated imager.

From Hologic, Inc. 30 Sep 2009

Secretary of State Clinton announces food security initiative

Secretary of State Hillary Rodham Clinton on Friday "unveiled … a food security initiative launched by the Obama administration to combat hunger worldwide," the Associated Press reports.

28 Sep 2009

Merck to distribute Afluria in the U.S. for CSL Biotherapies

CSL Biotherapies and its parent company, CSL Limited, one of the world's leading manufacturers of influenza vaccine, have reached an agreement with Merck & Co., Inc. on rights to market and distribute Afluria® in the United States under an exclusive, six-year agreement effective September 3, 2009.

28 Sep 2009

Cervical Cancer News and Research

Further Reading

Epitope spreading can get triggered by live, attenuated Listeria vaccine

Kaiser Permanente launches osteoporosis prevention campaign

Spectrascience receives Japanese patent for its Optical Biopsy Forceps System and Method of Sampling Tissue

NIH grants over $3.8 million to Asuragen

NCI awards $11.5 million grant to UAB for cervical cancer research

$16 million federal stimulus funds establish Seattle as national hub for cancer research

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

mtm laboratories signs additional tranche of Euro 7 million to its Series C funding

Group Health Research Institute to receive federal stimulus funds from ARRA

$16 million federal stimulus funds for cancer research projects

Guided Therapeutics awarded $2.5M NCI grant for marketing LightTouch technology

Inovio's SynCon H1N1 achieves protective antibody response against pandemic influenza in ferrets

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

Seattle Cancer Care Alliance launches TheDayIFoundOut website for cancer patients

Study points to subtle differences between boys and girls' attitudes to multiple drugs

Advaxis announces Phase I trial results of its ADXS11-001 therapeutic cancer vaccine

Screening and diagnostic tests contribute to health care value across spectrum of care

Hologic's ThinPrep integrated imager receives CE marking approval

Secretary of State Clinton announces food security initiative

Merck to distribute Afluria in the U.S. for CSL Biotherapies

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News